Mike has a broad academic background in chemistry, medicinal chemistry, biochemistry, molecular biology and cellular biology, which experience was greatly enhanced during nine years of cutting-edge research in fields of biochemistry and molecular biology. He has authored many peer-reviewed publications and is an inventor of many patents.
Before entering the patent profession, Mike spent two years at a highly successful start-up / spin-out biotechnology and gene therapy company. This experience taught him the importance of developing a strong and commercially relevant intellectual property (IP) portfolio, especially to early stage companies.
Mike has a depth of experience in contentious matters and particularly enjoys the advocacy of EPO Opposition and Appeal proceedings. Complementing such contentious matters, a significant proportion of Mike’s work relates to freedom to operate and due diligence projects, especially in relation to fund raising and IPOs. In addition, he advises multinational corporations on their global patent strategy and handles all related prosecution advice in multiple jurisdictions. Mike also has an active registered design practice and advises small and multinational clients on issues of freedom to operate and infringement of registered and unregistered designs.
Mike works across a broad range of technology disciplines, spanning biotechnology to engineering, including specialisms in gene therapy and gene regulation, protein-DNA binding interactions, AI-driven chemistry and biology, agritech, automated guidance and control systems, automotive engineering, medical and diagnostic devices, pharmaceuticals and petrochemicals.
Mike joined Keltie in 2006 having spent over three years with another top-tier London firm of patent and trade mark attorneys. He qualified as a Chartered Patent Attorney in 2006 and as a European Patent Attorney in 2008. He became a Partner at Keltie in 2014.
Looking back, in 1993 Mike graduated from the University of Cambridge with an honours degree in Natural Sciences, specialising in chemistry and biochemistry. He then moved to the University of Bristol, where he completed a PhD in Biochemistry. During his time at Bristol he was awarded first prize at an International conference for his research in engineering of the structure and function of bacterial proteins. Mike then moved to the renowned MRC Laboratory of Molecular Biology in Cambridge, where he carried out four years of research into DNA-binding proteins and gene regulation under the guidance of Nobel Laureate Professor Sir Aaron Klug, O.M. He spent two years at a start-up biotechnology company, Gendaq Ltd, where he combined the roles of Senior Scientist and Internal Patent Coordinator before entering the patent profession.
Mike has also been recognised in Legal 500 2024 edition.
06.02.2024Where fashion meets legality on social media
Unlock the secrets of the fashion world's legal runway with our latest article, featuring Keltie's collaboration with CITMA and UKFT.
16.06.2023Keltie ranked as one of Europe’s top Patent Law Firms
Keltie is proud to be ranked, once again, as one of Europe’s leading Patent Law Firms in the Financial Times 2023 Listings.
23.08.2021Five patents in Nanotechnology
OtherLess related knowledge